Metastatic Non-small Cell Lung Cancer Clinical Trials

DelveInsight reports that the Metastatic Non-Small Cell Lung Cancer pipeline includes over 25 key companies actively developing more than 30 treatment therapies.

Metastatic Non-small Cell Lung Cancer Overview:

Lung cancer remains a leading cause of cancer-related mortality worldwide, with generally poor outcomes. However, the advent of immune checkpoint inhibitors targeting programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) has revolutionized treatment for non-small cell lung cancer (NSCLC). Blocking the PD-1/PD-L1 pathway has shown notable therapeutic benefits and improved survival in both preclinical and clinical settings for patients with locally advanced or metastatic NSCLC.

PD-1, a type I transmembrane protein, is expressed on T cells, B cells, natural killer cells, activated monocytes, and dendritic cells. Its ligands, PD-L1 and PD-L2, are also type I transmembrane proteins but exhibit distinct expression patterns. PD-L1 is present on immune cells such as T cells, B cells, dendritic cells, and macrophages, as well as on various nonhematopoietic and tumor cells. Structurally, PD-1 and its ligands include a signal sequence, an immunoglobulin (Ig) domain, transmembrane regions, and a short cytoplasmic tail.

When PD-1 binds to PD-L1 or PD-L2, phosphorylation occurs at two tyrosine residues in its cytoplasmic domain. This triggers recruitment of the phosphatases SHP-1 and SHP-2, which interact with ITIM and ITSM motifs of PD-1, ultimately dampening antigen receptor signaling. This PD-1/ligand interaction suppresses effector T-cell activity, whereas the binding of B7-1/B7-2 to CD28 promotes T-cell proliferation.

Request for a detailed insights report on Metastatic Non-small Cell Lung Cancer pipeline insights

“Metastatic Non-small Cell Lung Cancer Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Metastatic Non-small Cell Lung Cancer Therapeutics Market.

Key Takeaways from the Metastatic Non-small Cell Lung Cancer Pipeline Report

• DelveInsight’s report highlights a dynamic Metastatic Non-Small Cell Lung Cancer (NSCLC) pipeline, with over 25 companies actively developing more than 30 investigational therapies. Leading players in this space include Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan Biotechnology, Genor Biopharma, among others, all working to advance novel treatment options for metastatic NSCLC.

• Several promising candidates—such as Zimberelimab, PM8002, RPH075, and others—are progressing through different stages of clinical development.

• Recent regulatory approvals have further strengthened the treatment landscape. In August 2024, the FDA approved AstraZeneca’s durvalumab for adult NSCLC patients following surgery, broadening its indication beyond advanced cases unsuitable for surgery. Earlier, in January 2023, the FDA approved pembrolizumab as an adjuvant therapy for patients with stage IB (T2a ≥4 cm), II, or IIIA NSCLC after surgical resection and platinum-based chemotherapy.

Metastatic Non-small Cell Lung Cancer Pipeline Analysis

The report provides insights into:

• The report provides detailed insights into the key companies that are developing therapies in the Metastatic Non-small Cell Lung Cancer Market.

• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Non-small Cell Lung Cancer treatment.

• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Metastatic Non-small Cell Lung Cancer market.

Download our free sample page report on Metastatic Non-small Cell Lung Cancer pipeline insights

Metastatic Non-small Cell Lung Cancer Emerging Drugs

• Zimberelimab: Arcus Biosciences

• PM8002: Biotheus

• RPH075: R-Pharm

Metastatic Non-small Cell Lung Cancer Companies

Over 25 leading companies are actively working on therapies for PD-1-positive Non-Small Cell Lung Cancer (PD-1+ NSCLC). Notably, Arcus Biosciences has drug candidates in the most advanced stage of development, currently in Phase III trials.

DelveInsight’s report covers around 30+ products under different phases of clinical development like

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I) along with the details of

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Metastatic Non-small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Metastatic Non-small Cell Lung Cancer Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Metastatic Non-small Cell Lung Cancer Therapies and Key Companies: Metastatic Non-small Cell Lung Cancer Clinical Trials and advancements

Metastatic Non-small Cell Lung Cancer Pipeline Therapeutic Assessment

• Metastatic Non-small Cell Lung Cancer Assessment by Product Type

• Metastatic Non-small Cell Lung Cancer By Stage

• Metastatic Non-small Cell Lung Cancer Assessment by Route of Administration

• Metastatic Non-small Cell Lung Cancer Assessment by Molecule Type

Download Metastatic Non-small Cell Lung Cancer Sample report to know in detail about the Metastatic Non-small Cell Lung Cancer treatment market @ Metastatic Non-small Cell Lung Cancer Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Metastatic Non-small Cell Lung Cancer Current Treatment Patterns

4. Metastatic Non-small Cell Lung Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Metastatic Non-small Cell Lung Cancer Late-Stage Products (Phase-III)

7. Metastatic Non-small Cell Lung Cancer Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Metastatic Non-small Cell Lung Cancer Discontinued Products

13. Metastatic Non-small Cell Lung Cancer Product Profiles

14. Metastatic Non-small Cell Lung Cancer Key Companies

15. Metastatic Non-small Cell Lung Cancer Key Products

16. Dormant and Discontinued Products

17. Metastatic Non-small Cell Lung Cancer Unmet Needs

18. Metastatic Non-small Cell Lung Cancer Future Perspectives

19. Metastatic Non-small Cell Lung Cancer Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Metastatic Non-small Cell Lung Cancer Pipeline Reports Offerings

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/